Target expression details
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T86591 | ||||
| Target Name | Nuclear receptor PPAR alpha | ||||
| Synonyms | PPAR-alpha; PPARalpha; Peroxisome proliferater-activated receptor alpha; PPARA | ||||
| Target Type | Successful | ||||
| Gene Name | PPARA | ||||
| Biochemical Class | Zinc-finger | ||||
| UniProt ID | PPARA_HUMAN | ||||
| Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
| Disease | Type 2 diabetes | ||||
| Example drug | CS-038 | Phase 3 | [524807], [1572592] | ||
| Tissue | Liver tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.17 Z-score: -0.30 P-value: 1.74E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | Romazarit | Preclinical | [544776], [1572592] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.35 Z-score: 0.96 P-value: 1.12E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Non-alcoholic fatty liver disease | ||||
| Example drug | GSK-677954 | Discontinued in Phase 2 | [536649], [1572592] | ||
| Tissue | Liver tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.25 Z-score: -0.67 P-value: 2.89E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Arteriosclerosis | ||||
| Example drug | LG-101280 | Discontinued in Phase 1 | [547284], [1572592] | ||
| Tissue | Peripheral blood | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.29 Z-score: -1.60 P-value: 1.54E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
|
|||||
| Reference | |||||
| Ref 544776 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000969) | ||||
| Ref 547284 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014823) | ||||
| Ref 536649 | Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.